Bank of New York Mellon Corp reported BENITEC BIOPHARMA INC (BNTC) in 12 quarterly 13F filings from 2025 Q2 through 2026 Q2. The latest visible filing shows BNTC at 0.00% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Bank of New York Mellon Corp's position in BENITEC BIOPHARMA INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
BNTC was reported at 0.00% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
These are the practical questions this page is built to answer before you even open the full history table.
Bank of New York Mellon Corp reported BNTC across 5 quarterly 13F filings, from 2025 Q2 through 2026 Q2.
The largest reported portfolio weight for BNTC was 0.00% in 2026 Q2.
The most recent filing on this page is 2026 Q2, when Bank of New York Mellon Corp reported 60,061 shares, equal to 0.00% of portfolio, with an estimated market value of $804K.
The chart compares Bank of New York Mellon Corp's quarterly BNTC portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent BNTC price moves, Bank of New York Mellon Corp correctly timed 4 out of 7 reported position changes (57%). The annualised alpha on BNTC relative to SPY over the holding period was -74.3%.